Press Release Archives - Page 13 of 23

Spectral Medical Inc. Closes $10.8 Million Public Offering and Concurrent Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Ontario– November 2, 2022 – Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce that it has closed its previously announced...

Spectral Medical Inc. Announces Pricing of Previously Announced Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Ontario– October 6, 2022 – Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce that further to its previously proposed...

Spectral Medical Inc. Announces Proposed Public Offering of Units and Private Placement of Notes

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Ontario– October 5, 2022 – Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce the launch of a proposed prospectus offering of...

Spectral Medical Provides Update on Tigris Clinical Trial

Robust recruitment activities experienced in closing weeks of September 44 patients now enrolled TORONTO, Canada – October 4, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for...

Spectral Announces FDA Approval to Add Up To 10 Additional Tigris Clinical Trial Sites

TORONTO, Canada – August 18, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the...

Spectral Medical Announces that its Wholly-Owned Subsidiary Dialco Medical and Distribution Partner Marathon Medical Awarded Contract to Provide SAMI Dialysis Devices to the US Department of Veterans Affairs

TORONTO, Canada – August 8, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.